---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112841"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:43:53.132261+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q3 2024: GAAP EPS $1.24, Non-GAAP $1.57; Sales $16.7B (+4% YoY)

## Summary
- Total worldwide sales $16.7B, up 4% (7% ex-FX). GAAP EPS $1.24; Non-GAAP EPS $1.57.
- KEYTRUDA sales $7.4B (+17% / 21% ex-FX). WINREVAIR sales $149M, gaining momentum.
- FY2024 guidance narrowed: sales $63.6B-$64.1B; Non-GAAP EPS $7.72-$7.77, includes $0.24/share net charge from Curon and Daiichi Sankyo deals.
- R&D expenses surged 77% to $5.9B, driven by $1.35B EyeBio acquisition and $750M Curon asset purchase.
- GARDASIL/GARDASIL 9 sales fell 11% due to lower China demand; Animal Health up 6% (11% ex-FX).

## SEC filing metadata
- accession: 0001104659-24-112841
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465924112841/0001104659-24-112841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465924112841/tm2426878d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112841
- JSON: https://secwatch.observer/filing/0001104659-24-112841.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112841.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.